This chapter describes the diagnosis, treatment, and prognosis for Hodgkin's lymphoma (HL) in pregnancy. The diagnosis of lymphoma requires a lymph node biopsy for pathological examination. The routine staging process for all lymphomas requires radiological evaluation usually with chest and abdominal computed tomography (CT). Abdominal and pelvic CT should be avoided during pregnancy. When magnetic resonance imaging (MRI) is available, it should be the modality of choice for the staging of lymphoma during pregnancy. Recently, positron emission tomography (PET)-CT has been increasingly used for both staging and treatment follow-up in patients with lymphoma. Although chemotherapy is currently recommended for the treatment of HL at all stages, radiotherapy can still be considered an appropriate treatment for stage 1. The most popular chemotherapy regimen for the treatment of HL is adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Adequate treatment with ABVD should be administered immediately at the beginning of the second trimester.

The relocation of ovaries for their protection in women diagnosed with cancer in the pelvis was mentioned as early as 1958 by McCall et al. At that time, the procedure was termed oophoropexy and considered to be revolutionary, controversial and "cutting edge" fertility preservation. Ovarian function is compromised when damaged during surgery, exposed to radiation, and/or chemotherapy. Chemotherapy has been found to have a highly variable chance of acute ovarian failure. In general, for gynecological malignancies, cervical and uterine cancers are the most likely indications for adjuvant or definitive radiation treatment to the pelvis, but pelvic radiation is also done for Hodgkin's lymphoma, pediatric sarcomas and rectal cancer. Ovarian function is almost guaranteed to be entirely lost without some intervention before pelvic radiation therapy. Ovarian transposition is a relatively simple option that should be considered with all patients at risk for ovarian failure due to radiation.

Sweet's syndrome (SS), also referred to as acute febrile neutrophilic dermatosis, is characterized by a constellation of symptoms and findings: fever, neutrophilia, erythematous and tender skin lesions that typically show an upper dermal infiltrate of mature neutrophils, and prompt improvement of both symptoms and lesions after the initiation of treatment with systemic corticosteroids. Many instances are related to lympho proliferative disorders such as acute and chronic leukemia, acute and chronic lymphatic leukemia, hairy cell leukemia, polycythemia vera, non-Hodgkin's lymphoma, Hodgkin's lymphoma, and other diseases of the hematopoietic system. Encephalitis and meningitis were the most common neurological manifestations. An elevated erythrocyte sedimentation rate (ESR) and peripheral leukocytosis with neutrophilia are the most consistent laboratory findings in SS. The standard therapy is administration of prednisone or prednisolone at an initial dose of 0.5-1.5 mg/kg body weight with a subsequent slow reduction over 2-4 weeks.